Genomewide RNAi screen identifies protein kinase Cβ and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis

Pigment Cell and Melanoma Research

Volumn 27, Issue 3, 2014, Pages 418-430

  Schönherr, Madeleine ^a   Bhattacharya, Animesh ^a   Kottek, Tina ^a   Szymczak, Silke ^b   Köberle, Margarethe ^c   Wickenhauser, Claudia ^a   Siebolts, Udo ^a   Saalbach, Anja ^a   Koczan, Dirk ^d   Magin, Thomas M ^a   Simon, Jan C ^a   Kunz, Manfred ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Intracellular signaling; Melanoma biology; RNA interference; Tumor metastasis

Indexed keywords

ENZASTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C BETA; SHORT HAIRPIN RNA; INDOLE DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CLONOGENESIS; COLONY FORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; DISTANT METASTASIS; FIBROBLAST; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC SCREENING; HUMAN; HUMAN CELL; MELANOCYTIC NEVUS; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; RNA INTERFERENCE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL DIVISION; CELL MOTION; DNA MICROARRAY; DRUG EFFECTS; DRUG SCREENING; ENZYME INDUCTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETIC TRANSDUCTION; GENETICS; LUNG NEOPLASMS; MELANOMA; PATHOLOGY; PHYSIOLOGY; PIGMENTED NEVUS; SECONDARY; SIGNAL TRANSDUCTION; SKIN TUMOR; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC LIBRARY; HUMANS; INDOLES; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; NEVUS, PIGMENTED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE C BETA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TRANSDUCTION, GENETIC; TUMOR STEM CELL ASSAY; UP-REGULATION;

EID: 84898856348     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12216     Document Type: Article

References (68)

1. Alexaki, V.I., Javelaud, D., and Mauviel, A. (2008). JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis. Pigment Cell Melanoma Res. 21, 429-438.
2. Alla, V., Engelmann, D., Niemetz, A., Pahnke, J., Schmidt, A., Kunz, M., Emmrich, S., Steder, M., Koczan, D., and Putzer, B.M. (2010). E2F1 in melanoma progression and metastasis. J. Natl. Cancer Inst. 102, 127-133.
3. Arora, A., and Scholar, E.M. (2005). Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971-979.
4. Baselga, J. (2006). Targeting tyrosine kinases in cancer: the second wave. Science 312, 1175-1178.
5. Bhatia, S., and Thompson, J.A. (2012). Systemic therapy for metastatic melanoma in 2012: dawn of a new era. J. Natl. Compr. Canc. Netw. 10, 403-412.
6. Bhattacharya, A., Schmitz, U., Wolkenhauer, O., Schonherr, M., Raatz, Y., and Kunz, M. (2013). Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene 32, 3175-3183.
7. Brettschneider, J., Collin, F., Bolstad, B.M., and Speed, T.P. (2008). Quality assessment for short oligonucleotide microarray data. Technometrics 50, 241-264.
8. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
9. Clark, A.S., West, K.A., Blumberg, P.M., and Dennis, P.A. (2003). Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res. 63, 780-786.
10. Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
11. Dahlman, K.B., Parker, J.S., Shamu, T., Hieronymus, H., Chapinski, C., Carver, B., Chang, K., Hannon, G.J., and Sawyers, C.L. (2012). Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS One 7, e34414.
12. Dai, M., Wang, P., Boyd, A.D. et al. (2005). Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175.
13. Daud, A., and Bastian, B.C. (2012). Beyond BRAF in melanoma. Curr. Top. Microbiol. Immunol. 355, 99-117.
14. Denning, M.F. (2012). Specifying protein kinase C functions in melanoma. Pigment Cell Melanoma Res. 25, 466-476.
15. Dorvault, C.C., Weilbaecher, K.N., Yee, H., Fisher, D.E., Chiriboga, L.A., Xu, Y., and Chhieng, D.C. (2001). Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens. Cancer 93, 337-343.
16. Dummer, R., and Flaherty, K.T. (2012). Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr. Opin. Oncol. 24, 150-154.
17. Easty, D.J., Gray, S.G., O'Byrne, K.J., O'Donnell, D., and Bennett, D.C. (2011). Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res. 24, 446-461.
18. Engers, R., Mrzyk, S., Springer, E., Fabbro, D., Weissgerber, G., Gernharz, C.D., and Gabbert, H.E. (2000). Protein kinase C in human renal cell carcinomas: role in invasion and differential isoenzyme expression. Br. J. Cancer 82, 1063-1069.
19. Fields, A.P., Calcagno, S.R., Krishna, M., Rak, S., Leitges, M., and Murray, N.R. (2009). Protein kinase Cbeta is an effective target for chemoprevention of colon cancer. Cancer Res. 69, 1643-1650.
20. Garnett, M.J., and Marais, R. (2004). Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313-319.
21. Gilhooly, E.M., Morse-Gaudio, M., Bianchi, L., Reinhart, L., Rose, D.P., Connolly, J.M., Reed, J.A., and Albino, A.P. (2001). Loss of expression of protein kinase C beta is a common phenomenon in human malignant melanoma: a result of transformation or differentiation? Melanoma Res. 11, 355-369.
22. Gokmen-Polar, Y., Murray, N.R., Velasco, M.A., Gatalica, Z., and Fields, A.P. (2001). Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res. 61, 1375-1381.
23. Graff, J.R., McNulty, A.M., Hanna, K.R. et al. (2005). The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65, 7462-7469.
24. Gupta-Rossi, N., Ortica, S., Meas-Yedid, V., Heuss, S., Moretti, J., Olivo-Marin, J.C., and Israel, A. (2011). The adaptor-associated kinase 1, AAK1, is a positive regulator of the notch pathway. J. Biol. Chem. 286, 18720-18730.
25. Hans, C.P., Weisenburger, D.D., Greiner, T.C. et al. (2005). Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod. Pathol. 18, 1377-1384.
26. Hsiao, W.L., Housey, G.M., Johnson, M.D., and Weinstein, I.B. (1989). Cells that overproduce protein kinase C are more susceptible to transformation by an activated H-ras oncogene. Mol. Cell. Biol. 9, 2641-2647.
27. Hubbell, E., Liu, W.M., and Mei, R. (2002). Robust estimators for expression analysis. Bioinformatics 18, 1585-1592.
28. Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U., and Speed, T.P. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264.
29. Jackson, A.L., and Linsley, P.S. (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 9, 57-67.
30. Kondo, S., Lu, Y., Debbas, M. et al. (2003). Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc. Natl. Acad. Sci. USA 100, 5431-5436.
31. Koren, R., Ben, M.D., Langzam, L., Dekel, Y., Konichezky, M., Baniel, J., Livne, P.M., Gal, R., and Sampson, S.R. (2004). Expression of protein kinase C isoenzymes in benign hyperplasia and carcinoma of prostate. Oncol. Rep. 11, 321-326.
32. Lee, D., Park, S.J., Sung, K.S. et al. (2012). Mdm2 associates with Ras effector NORE1 to induce the degradation of oncoprotein HIPK1. EMBO Rep. 13, 163-169.
33. Liu, Y., Su, W., Thompson, E.A., Leitges, M., Murray, N.R., and Fields, A.P. (2004). Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J. Biol. Chem. 279, 45556-45563.
34. Lopez-Bergami, P., Huang, C., Goydos, J.S. et al. (2007). Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11, 447-460.
35. Lutzny, G., Kocher, T., Schmidt-Supprian, M. et al. (2013). Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 23, 77-92.
36. McGill, G.G., Horstmann, M., Widlund, H.R. et al. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109, 707-718.
37. Miller, A.J., and Mihm, M.C. Jr (2006). Melanoma. N. Engl. J. Med. 355, 51-65.
38. Mohr, S., Bakal, C., and Perrimon, N. (2010). Genomic screening with RNAi: results and challenges. Annu. Rev. Biochem. 79, 37-64.
39. Natarajan, N., Telang, S., Miller, D., and Chesney, J. (2011). Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 71, 1233-1250.
40. Nateri, A.S., Spencer-Dene, B., and Behrens, A. (2005). Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 437, 281-285.
41. Ngo, V.N., Davis, R.E., Lamy, L. et al. (2006). A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106-110.
42. Oka, M., Nishigori, C., Kageshita, T., Hsu, M.Y., Penmatcha, S., and Herlyn, M. (2006). Expression of PKC isoforms in human melanocytic cells in situ. J. Dermatol. Sci. 41, 157-161.
43. Park, H.Y., Perez, J.M., Laursen, R., Hara, M., and Gilchrest, B.A. (1999). Protein kinase C-beta activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain. J. Biol. Chem. 274, 16470-16478.
44. Park, H.Y., Wu, H., Killoran, C.E., and Gilchrest, B.A. (2004). The receptor for activated C-kinase-I (RACK-I) anchors activated PKC-beta on melanosomes. J. Cell Sci. 117, 3659-3668.
45. Park, H.Y., Wu, C., Yonemoto, L., Murphy-Smith, M., Wu, H., Stachur, C.M., and Gilchrest, B.A. (2006). MITF mediates cAMP-induced protein kinase C-beta expression in human melanocytes. Biochem. J. 395, 571-578.
46. Patel, S.P., and Kim, K.B. (2012). Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opin. Investig. Drugs 21, 531-539.
47. Paulsen, R.D., Soni, D.V., Wollman, R. et al. (2009). A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol. Cell 35, 228-239.
48. Plastaras, J.P., Kim, S.H., Liu, Y.Y. et al. (2007). Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 67, 9443-9454.
49. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B., and Rosen, N. (2009). (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 106, 4519-4524.
50. Quatrale, A.E., Porcelli, L., Silvestris, N., Colucci, G., Angelo, A., and Azzariti, A. (2011). EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front. Biosci. 16, 1962-1972.
51. Romano, S., Nappo, G., Cali, G. et al. (2013). Synergy between enzastaurin doxorubicin in inducing melanoma apoptosis. Pigment Cell Melanoma Res. 26, 900-911.
52. Roskoski, R. Jr (2012). ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol. Res. 66, 105-143.
53. Ryu, B., Kim, D.S., Deluca, A.M., and Alani, R.M. (2007). Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS One 2, e594.
54. Saalbach, A., Klein, C., Schirmer, C., Briest, W., Anderegg, U., and Simon, J.C. (2010). Dermal fibroblasts promote the migration of dendritic cells. J. Invest. Dermatol. 130, 444-454.
55. Sakurai, T., Maeda, S., Chang, L., and Karin, M. (2006). Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. USA 103, 10544-10551.
56. Samija, I., Lukac, J., Maric-Brozic, J., and Kusic, Z. (2004). Microphthalmia-associated transcription factor and tyrosinase as markers of melanoma cells in blood of patients with melanoma. Croat Med J. 45, 142-148.
57. Schubert, K., Gutknecht, D., Koberle, M., Anderegg, U., and Saalbach, A. (2013). Melanoma cells use Thy-1 (CD90) on endothelial cells for metastasis formation. Am. J. Pathol. 182, 266-276.
58. Schultz, J., Lorenz, P., Gross, G., Ibrahim, S., and Kunz, M. (2008). MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 18, 549-557.
59. Shields, J.M., Thomas, N.E., Cregger, M. et al. (2007). Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res. 67, 1502-1512.
60. Szklarczyk, D., Franceschini, A., Kuhn, M. et al. (2011). The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561-D568.
61. Thomas, P.D., Campbell, M.J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., Diemer, K., Muruganujan, A., and Narechania, A. (2003). PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 13, 2129-2141.
62. Ultanir, S.K., Hertz, N.T., Li, G., Ge, W.P., Burlingame, A.L., Pleasure, S.J., Shokat, K.M., Jan, L.Y., and Jan, Y.N. (2012). Chemical genetic identification of NDR1/2 kinase substrates AAK1 and Rabin8 Uncovers their roles in dendrite arborization and spine development. Neuron 73, 1127-1142.
63. Vo, B.T., Morton, D. Jr, Komaragiri, S., Millena, A.C., Leath, C., and Khan, S.A. (2013). TGF-beta effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway. Endocrinology 154, 1768-1779.
64. Voris, J.P., Sitailo, L.A., Rahn, H.R., Defnet, A., Gerds, A.T., Sprague, R., Yadav, V., Caroline Le Poole, I., and Denning, M.F. (2010). Functional alterations in protein kinase C beta II expression in melanoma. Pigment Cell Melanoma Res. 23, 216-224.
65. Weston, C.R., and Davis, R.J. (2007). The JNK signal transduction pathway. Curr. Opin. Cell Biol. 19, 142-149.
66. Wu, E.X., Aguiar, R.C.T., Savage, K.J., Kutok, J.L., Wang, F.F., Aster, J.C., and Shipp, M.A. (2002). PKC beta: a rational therapeutic target in diffuse large B-cell lymphoma. Blood 100, 202A.
67. Wu, X., Zhu, M., Fletcher, J.A., Giobbie-Hurder, A., and Hodi, F.S. (2012). The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 7, e29622.
68. Yu, W., Murray, N.R., Weems, C., Chen, L., Guo, H., Ethridge, R., Ceci, J.D., Evers, B.M., Thompson, E.A., and Fields, A.P. (2003). Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis. J. Biol. Chem. 278, 11167-11174.